A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

LY3537982

Administered orally.

Trial Locations (3)

Jilin Cancer Hospital, Changchun

The First Affiliated Hospital, Zhejiang University, Hangzhou

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06235983 - A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter